Disclosed are 2-(phenoxy)-thiazolo[4,5-b]pyridine, thiazolo[4,5-c]pyridine, thiazolo[5,4-b]pyridine, thiazolo[5,4-c]pyridine and thiazolo[4,5-b]pyrazine derivatives as represented by the general formula (I), wherein X4, X5, X6, and X7 are defined as a) one of X4, X5, X6 and X7 is N and the others are CRa, or b) each of X4 and X7 are N and each of X5 and X6 is CH A is -CH2-, -CH2CH2-, or -OCH2CH2- and where the remaining substituents are as defined herein. Representative compounds include 2-(4-{ 2-[4-(pyrimidin-2-yloxy)piperidin-1-yl]ethoxy} phenoxy)[1,3]thiazolo[4,5-b]pyridine, meso-2-(4-{ 2-[8-acetyl-3,8-diazabicyclo[3.2.1]oct-3-yl]ethyl} phenoxy)-7-methyl[1,3]thiazolo[4,5-b]pyridine, 2-({ 4-[(4-pyridin-4-ylpiperidin-1-yl)methyl]phenyl} oxy)[1,3]thiazolo[4,5-c]pyridine, N-(cyclopropylmethyl)-N-[4-([1,3]thiazolo[5,4-c]pyridin-2-yloxy)benzyl]propane-1,3-diamine and 1-{ 2-[4-([1,3]thiazolo[4,5-b]pyrazin-2-yloxy)phenoxy]ethyl} -4-[3-(trifluoromethyl)phenyl]piperidin-4-ol. Further disclosed is a pharmaceutical composition which comprises an effective amount of at least one compounds of Formula (I) as defined above, or the pharmaceutically acceptable salts, and solvates thereof, for modulating leukotriene A4 hydrolase activity, and particularly for the treatment of inflammatory disorders, allergic disorders, dermatological disorders, autoimmune disease, lymphatic disorders, and immunodeficiency disorders.
